Literature DB >> 27464590

Direct and Indirect Economic Burden of Chronic Liver Disease in the United States.

Maria Stepanova1, Leyla De Avila2, Mariam Afendy3, Issah Younossi3, Huong Pham3, Rebecca Cable3, Zobair M Younossi4.   

Abstract

BACKGROUND & AIMS: Chronic liver (CLD) is a major public health concern. We assessed its effects on quality of life and work productivity, as well as its economic burden in the United States.
METHODS: We performed a cross-sectional study of data from the Medical Expenditure Panel Survey (MEPS; 2004-2013). We extracted participants' sociodemographic parameters and medical histories. Subjects with CLD were identified based on Clinical Classification Software codes. MEPS participants were compared between those with and without CLD, and then between employed and unemployed patients with CLD. Outcomes were quality-of-life scores, employment, and health care use.
RESULTS: We collected data from 230,406 adult participants (age, ≥18 y) in the MEPS; 1846 had current CLD (36.7% with viral hepatitis and 5.3% with liver cancer). Individuals with CLD were less likely to be employed (44.7% vs 69.6% patients without CLD), were not working owing to illness/disability (30.5% vs 6.6% without CLD), lost more work because of disability (10.2 vs 3.4 d without CLD), and had more health care use, producing greater health care expenses ($19,390 vs $5567/y without CLD) (all P < .0001). Patients with CLD also had more comorbidities and worse self-reported general and mental health status, and reported more health-related limitations in their daily activities than individuals without CLD (all P < .0001). They also indicated more psychologic distress and depressive symptoms and had a lower quality of life and health utility scores (P < .0001). In multivariate analysis, after adjustment for sociodemographic factors and comorbidities, the presence of CLD was an important predictor of unemployment (odds ratio, 0.60; 95% confidence interval, 0.50-0.70), annual health care expenditure (β = $9503 ± $2028), and impairment in all aspects of health-related quality of life (all P < .0001). In patients with CLD, the presence of liver cancer had the most profound impact on health care expenditures (β = $17,278 ± $5726/y) and physical health (β = -7.2 ± 1.7 for SF-12 physical component) (all P < .005).
CONCLUSIONS: In a cross-sectional analysis of MEPS participants, we associated CLD with large economic and quality-of-life burdens.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Costs; HRQOL; NAFLD; Population

Mesh:

Year:  2016        PMID: 27464590     DOI: 10.1016/j.cgh.2016.07.020

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  38 in total

1.  Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic.

Authors:  Iliana Doycheva; Kymberly D Watt; Ghassoub Rifai; Rachel Abou Mrad; Rocio Lopez; Nizar N Zein; William D Carey; Naim Alkhouri
Journal:  Dig Dis Sci       Date:  2017-02-13       Impact factor: 3.199

2.  The Association of Abnormal Liver Tests with Hepatitis C Testing in Primary Care.

Authors:  Andrew D Schreiner; John Bian; Jingwen Zhang; Z Merle Haulsee; Justin Marsden; Valerie Durkalski-Mauldin; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Am J Med       Date:  2019-07-29       Impact factor: 4.965

3.  Long-term albumin administration in decompensated cirrhosis.

Authors:  Feyzi Bostan; Ayhan Hilmi Çekin
Journal:  Turk J Gastroenterol       Date:  2019-04       Impact factor: 1.852

4.  Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis.

Authors:  Jasmohan S Bajaj; Payam Matin; Melanie B White; Andrew Fagan; Janina Golob Deeb; Chathur Acharya; Swati S Dalmet; Masoumeh Sikaroodi; Patrick M Gillevet; Sinem E Sahingur
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-08-17       Impact factor: 4.052

5.  Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis.

Authors:  Shirley Cohen-Mekelburg; Akbar K Waljee; Brooke C Kenney; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-09       Impact factor: 11.382

6.  Association of Depression Risk with Patient Experience, Healthcare Expenditure, and Health Resource Utilization Among Adults with Atherosclerotic Cardiovascular Disease.

Authors:  Victor Okunrintemi; Javier Valero-Elizondo; Erin D Michos; Joseph A Salami; Oluseye Ogunmoroti; Chukwuemeka Osondu; Martin Tibuakuu; Eve-Marie Benson; Timothy M Pawlik; Michael J Blaha; Khurram Nasir
Journal:  J Gen Intern Med       Date:  2019-09-05       Impact factor: 5.128

7.  The Burden of Hepatobiliary Diseases in Portugal: What Can We Learn from Mortality Data.

Authors:  A Simão
Journal:  GE Port J Gastroenterol       Date:  2017-12-08

Review 8.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

9.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

10.  Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Andrew Fagan; Melanie B White; James B Wade; Phillip B Hylemon; Douglas M Heuman; Michael Fuchs; Binu V John; Chathur Acharya; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Gastroenterol       Date:  2019-07       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.